Hypertension as a Key Driver of Liver Fibrosis Progression and Adverse Outcomes in MASLD: Evidence from Large Cohorts

Highlight

• Hypertension is highly prevalent in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).
• Hypertension independently increases the risk of adverse clinical outcomes including mortality, cardiovascular, and liver-related events in MASLD.
• Hypertension is associated with accelerated progression of liver stiffness and histologic fibrosis in MASLD.
• These findings underscore the importance of multidisciplinary management and fibrosis screening in MASLD patients with hypertension.

Study Background